ストックスクリーナーアプリを入手
0.2485
2.05%
0.005
プレマーケット:
.25
0.0015
+0.60%
前日終値:
$0.2435
開ける：
$0.2463
24時間の取引高:
1.39M
Relative Volume:
0.62
時価総額：
$10.26M
収益：
-
当期純損益:
$-37.75M
株価収益率:
-0.0765
EPS:
-3.25
ネットキャッシュフロー:
$-30.91M
1週間 パフォーマンス:
-9.64%
1か月 パフォーマンス:
+5.74%
6か月 パフォーマンス:
-90.14%
1年 パフォーマンス:
-92.86%
1日の値動き範囲:
$0.234
$0.2499
1週間の範囲:
$0.2298
$0.2666
52週間の値動き範囲:
$0.224
$4.45
Cellectar Biosciences Inc Stock (CLRB) Company Profile
名前
Cellectar Biosciences Inc
セクター
電話
(608) 441-8120
住所
100 CAMPUS DRIVE, FLORHAM PARK, NJ
CLRB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
0.2485 | 10.26M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-05 | 再開されました | Ladenburg Thalmann | Buy |
| 2020-07-01 | 開始されました | Oppenheimer | Outperform |
| 2020-01-21 | 再開されました | ROTH Capital | Buy |
| 2019-09-13 | 開始されました | ROTH Capital | Buy |
| 2016-12-21 | 開始されました | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
Barclays PLC Trims Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (STU:NV4) Enterprise Value : €-9.79 Mil (As of Jan. 19, 2025) - GuruFocus.com
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Cellectar Biosciences (FRA:NV4) Gross Margin % : 0.00% (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Oppenheimer keeps Perform rating on Cellectar Biosciences stock on recent update - Investing.com Canada
Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com - Defense World
Cellectar Biosciences to Highlight 2025 Strategic - GlobeNewswire
Cellectar's Cancer Drug Iopofosine Achieves Remarkable 83.6% Response Rate in Phase 2 Trial - StockTitan
S&P Midcap 400 (IDX) QuotePress Release - The Globe and Mail
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
Barclays PLC Has $258,000 Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar stock plunges 50% post-market on restructuring news - MSN
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World
Wall Street’s top 5 stocks with the biggest upside in 2025Finbold - Finbold - Finance in Bold
Is Now The Time To Buy Cellectar Biosciences Inc (NASDAQ: CLRB) Stock? - Stocks Register
Neuroblastoma Therapeutic Market: Analyzing the Impact of High - openPR
Oppenheimer Downgrades Cellectar Biosciences (CLRB) - MSN
Roth Capital Has Optimistic Outlook of CLRB Q1 Earnings - Defense World
Cellectar Biosciences Implements Workforce Reduction Plan to Enhance Operational Efficiency - Defense World
Cellectar Biosciences (FRA:NV4) 10-Year Sharpe Ratio : -0.19 (As of Dec. 12, 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) 3-Year Sortino Ratio : -0.47 (As of Dec. 12, 2024) - GuruFocus.com
Cellectar Biosci stock hits 52-week low at $0.27 amid sharp decline - Investing.com
Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut - MarketWatch
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options - Benzinga
Cellectar Biosciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Cellectar stock plunges 50% post-market on restructuring news (NASDAQ:CLRB) - Seeking Alpha
CLRBCellectar Biosciences INC NEW Latest Stock News & Market Updates - StockTitan
Cellectar refocuses on solid tumor radiotherapies - Investing.com
Cellectar Biosciences Provides Strategic Update on Clinical - GlobeNewswire
Cellectar Shifts Strategy After FDA Feedback, Cuts 60% Workforce to Advance Cancer Pipeline - StockTitan
Waldenstrom Macroglobulinemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp - Barchart
Waldenstrom Macroglobulinemia Market Growth to Accelerate - openPR
Cellectar Biosci stock hits 52-week low at $1.38 By Investing.com - Investing.com Canada
Cellectar Biosci stock hits 52-week low at $1.38 - Investing.com
Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target - Quantisnow
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? - AOL
Cellectar Biosciences (STU:NV4) Forward Dividend Yield % : 0.00% (As of Dec. 01, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Volatility : 73.35% (As of Nov. 29, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Total Stockholders Equity : €13.66 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) PE Ratio : At Loss (As of Nov. 28, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Other Long Term Assets : €0.03 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Current Accrued Expense : €7.48 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Quick Ratio : 1.77 (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) 3-Year Book Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) Margin of Safety % (DCF FCF Based) : N/A (As of Nov. 26, 2024) - GuruFocus.com
CLRB (Cellectar Biosciences) EPS without NRI : $-2.17 (TTM As of Sep. 2024) - GuruFocus.com
12,500 Shares in Cellectar Biosciences, Inc. (NASDAQ:CLRB) Purchased by Oppenheimer & Co. Inc. - Defense World
Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
Cellectar Biosciences Inc (CLRB) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):